June Almenoff

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Novel statistical tools for monitoring the safety of marketed drugs
    J S Almenoff
    Department of Epidemiology and Population Health, Safety Evaluation and Risk Management, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Clin Pharmacol Ther 82:157-66. 2007
  2. ncbi Innovations for the future of pharmacovigilance
    June S Almenoff
    Safety Evaluation and Risk Management, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Drug Saf 30:631-3. 2007
  3. ncbi Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting
    June S Almenoff
    GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, Five Moore Drive, PO Box 13398, 5 4214 4C, Research Triangle Park, NC 27709 3398, USA
    Pharmacoepidemiol Drug Saf 12:517-21. 2003
  4. ncbi Perspectives on the use of data mining in pharmaco-vigilance
    June Almenoff
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Drug Saf 28:981-1007. 2005
  5. ncbi Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department
    June S Almenoff
    Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Research Triangle Park, North Carolina 27709 3398, USA
    Drug Saf 29:875-87. 2006
  6. ncbi Evolving paradigms in pharmacovigilance
    Wendy Brewster
    GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, Harlow, UK
    Curr Drug Saf 1:127-34. 2006
  7. ncbi Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data
    William DuMouchel
    AT and T Labs Research, Florham Park, New Jersey, USA
    Clin Ther 26:1092-1104. 2004

Collaborators

Detail Information

Publications7

  1. ncbi Novel statistical tools for monitoring the safety of marketed drugs
    J S Almenoff
    Department of Epidemiology and Population Health, Safety Evaluation and Risk Management, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Clin Pharmacol Ther 82:157-66. 2007
    ..We also provide examples of how these tools can be used to identify novel drug interactions and demographic risk factors for adverse drug reactions. Challenges, controversies, and frontiers for future research are discussed...
  2. ncbi Innovations for the future of pharmacovigilance
    June S Almenoff
    Safety Evaluation and Risk Management, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Drug Saf 30:631-3. 2007
    ..In summary, the implementation of OSM provides new tools and efficient processes to advance the science of pharmacovigilance...
  3. ncbi Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting
    June S Almenoff
    GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, Five Moore Drive, PO Box 13398, 5 4214 4C, Research Triangle Park, NC 27709 3398, USA
    Pharmacoepidemiol Drug Saf 12:517-21. 2003
  4. ncbi Perspectives on the use of data mining in pharmaco-vigilance
    June Almenoff
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Drug Saf 28:981-1007. 2005
    ..The availability of a publicly accessible global safety database, which is updated on a frequent basis, would further enhance detection and communication about safety issues...
  5. ncbi Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department
    June S Almenoff
    Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Research Triangle Park, North Carolina 27709 3398, USA
    Drug Saf 29:875-87. 2006
    ....
  6. ncbi Evolving paradigms in pharmacovigilance
    Wendy Brewster
    GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, Harlow, UK
    Curr Drug Saf 1:127-34. 2006
    ..In summary, the information outlined in this paper provides a valuable benchmark for risk management and pharmacovigilance in pharmaceutical development...
  7. ncbi Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data
    William DuMouchel
    AT and T Labs Research, Florham Park, New Jersey, USA
    Clin Ther 26:1092-1104. 2004
    ..Churg-Strauss syndrome (CSS), also known as allergic granulomatous angiitis (AGA), is a rare vasculitis that occurs in patients with bronchial asthma. The nature of the association of CSS with various asthma therapies is unclear...